Olaparib
Active pharmaceutical substance formulated in Jan Aushadhi generic products for Oncology & Critical Care treatment.
🧴 Clinical Application
Take orally 300 mg (two 150 mg tablets) twice daily, approximately 12 hours apart with or without food with a full glass of water. Swallow whole; do not chew, crush, or dissolve.
⚠️ Side Effects
Common: Nausea, fatigue, anemia (often requires blood transfusions), vomiting, diarrhea, dysgeusia, neutropenia, thrombocytopenia. Rare/Severe: Myelodysplastic syndrome (MDS) / Acute Myeloid Leukemia (AML in ~1.5% of patients), and pneumonitis.
🛡️ Safety Warnings
Black Box Warning: Myelodysplastic syndrome and acute myeloid leukemia (MDS/AML); monitor complete blood count monthly. If severe hematologic toxicity occurs, interrupt therapy until counts recover. Embryofetal toxicity; verified contraception is mandatory.
Jan Aushadhi Products containing Olaparib
Found 2 generic formulation(s) containing this active ingredient.
Olaparib Tablet 100 mg
Olaparib Tablets (100mg, 150mg) is a first-in-class oral poly(ADP-ribose) polymerase (PARP-1, PARP-2, PARP-3) inhibitor on the WHO Model List of Essential Medicines. It traps inactivated PARP enzymes at single-strand DNA breaks, transforming them into lethal double-strand breaks during replication. In homologous recombination deficiency (HRD) tumors (e.g., BRCA1 or BRCA2 germline or somatic mutations), cancer cells cannot repair double-strand breaks, triggering synthetic lethality and tumor apoptosis while sparing normal cells. Indicated for maintenance therapy in BRCA-mutated advanced ovarian cancer, HER2-negative metastatic breast cancer with germline BRCA mutation, metastatic pancreatic adenocarcinoma, and HRR gene-mutated metastatic castration-resistant prostate cancer.
Olaparib Tablet 150 mg
Olaparib Tablets (100mg, 150mg) is a first-in-class oral poly(ADP-ribose) polymerase (PARP-1, PARP-2, PARP-3) inhibitor on the WHO Model List of Essential Medicines. It traps inactivated PARP enzymes at single-strand DNA breaks, transforming them into lethal double-strand breaks during replication. In homologous recombination deficiency (HRD) tumors (e.g., BRCA1 or BRCA2 germline or somatic mutations), cancer cells cannot repair double-strand breaks, triggering synthetic lethality and tumor apoptosis while sparing normal cells. Indicated for maintenance therapy in BRCA-mutated advanced ovarian cancer, HER2-negative metastatic breast cancer with germline BRCA mutation, metastatic pancreatic adenocarcinoma, and HRR gene-mutated metastatic castration-resistant prostate cancer.
Brand Equivalents & Price Comparison
Compare Jan Aushadhi generic prices against popular commercial brands for Olaparib.
| Generic Formulation | Pack Size | Jan Aushadhi Price | Commercial Brand Equivalents | Avg. Commercial Price | Savings |
|---|---|---|---|---|---|
| Olaparib Tablet 100 mg | 30's in bottle | Under Process | N/A | N/A | N/A |
| Olaparib Tablet 150 mg | 30's in bottle | Under Process | N/A | N/A | N/A |
Frequently Asked Questions (FAQ)
Get answers to common queries about Olaparib generics.